Moderna nelle notizie
Sviluppo di farmaci basati su mRNA
Tamtam ha trovato 20 articoli recenti su Moderna.
- Moderna’s Surprise Rally Defies Bears Amid New Vaccine Hopes
- Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
- The Melanoma Win Is Real, The Price Isn't - Moderna And MRNY Both Sell (NASDAQ:MRNA)
- Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
- What Analysts Are Saying About Moderna Stock
- Moderna downgraded to neutral at UBS on questions over revenue growth
- Moderna just had its best day since October. Here's what's going on, and what analysts expect
- BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating
- Why Moderna Shares Are Quietly Climbing Off the Lows
- Moderna stock price target raised to $24 from $21 at BofA Securities
- Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound
- Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches
- Moderna issues shareholder letter under Regulation FD disclosure
- Moderna, Inc. Reports 2025 Achievements and 2026 Outlook
- Moderna, searching for a rebound, to seek approval of mRNA flu shot
- Moderna Submits Application for mRNA-Based Seasonal Flu Vaccine Approval
- Moderna seeks flu vaccine approvals; Neumora Alzheimer’s data
- Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
- Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
- Why Is Moderna (MRNA) Stock Rocketing Higher Today
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Moderna?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili